Cresset has launched Fieldstere, software that enables medicinal chemists to enrich their shortlist of drug candidates with diverse compounds that share the same biological activity (bioisosteres).
These non-obvious compounds can represent product opportunities unprotected by existing patents.
Fieldstere allows the fine-tuning of bioisosteres to enhance potency and specificity while removing undesirable ADME and physical properties.
It builds on Cresset's Field technology, which describes chemical structures in terms of the surface properties of the whole molecule.
These determine, much more accurately than existing tools, how a compound will interact with other molecules.
As a result, Fieldstere has application in the development of patent strategy for the protection of molecular entities, identifying follow-on compounds as marketed products.
